Global Market Study on Biologics Contract Manufacturing Demand: Strong Biologics Pipeline to Rapidly Surge Market Growth

Global Market Study on Biologics Contract Manufacturing Demand: Strong Biologics Pipeline to Rapidly Surge Market Growth

  • Persistence Market Research
  • September 2020
  • Biotechnology
  • 293 pages

Report Description

1
1

Biologics Contract Manufacturing Demand - Scope of the Report

Persistence Market Research (PMR) recently published a market study on the global market for biologics contract manufacturing demand. The study provides detailed assessment on key market dynamics, including the drivers, trends, opportunities, restraints, and detailed information about the biologics contract manufacturing demand structure. The market study presents exclusive information about how biologics contract manufacturing demand will grow during the forecast period of 2020-2030.

Key indicators of market growth, which include Year-on-Year (Y-o-Y) growth of the market, and compounded annual growth rate (CAGR) are explained in PMR’s study in a comprehensive manner. This information can help readers understand the quantitative growth prospects of biologics contract manufacturing demand during the forecast period.

The study is relevant for stakeholders interested in biologics contract manufacturing demand, including biologics contract manufacturing service organizations, suppliers, distributors, and investors, and can help them in developing appropriate strategies to grow in the market. Stakeholders in biologics contract manufacturing demand, investors, industry experts, researchers, and journalists, as well as business researchers can leverage the information and data presented in PMR’s study.

The study also includes statistics as well as facts related to the macro- as well as micro-economic factors that are impacting developments in the market. It also offers actionable insights based on the future trends regarding biologics contract manufacturing demand. Furthermore, small businesses and new entrants related to biologics contract manufacturing demand too can make use of the information presented in this study, based on which, they can make appropriate business decisions to gain momentum in the market.

Key Segments of Biologics Contract Manufacturing Demand

PMR’s study on biologics contract manufacturing demand offers information divided into five important segments— product, platform, application, therapeutic area, and region. This report offers comprehensive data and information about the important market dynamics and growth parameters associated with these categories.

Product

  • Monoclonal Antibodies
  • Vaccines
  • Growth Factors
  • Interferons
  • Recombinant Hormones
  • Insulin
  • Others

Platform

  • Mammalian
  • Microbial

Application

  • Clinical
  • Commercial

Therapeutic Area

  • Autoimmune Diseases
  • Oncology
  • Metabolic Diseases
  • Ophthalmology
  • Cardiovascular Diseases
  • Infectious Diseases
  • Neurology
  • Respiratory Disorders
  • Others

Region

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • Middle East and Africa (MEA)

Key Questions Answered in PMR’s Biologics Contract Manufacturing Demand Study

  • How will CDMO services demand unfold over the coming years?
  • Which regions will continue to remain the most profitable regional markets for players dealing with biologics contract manufacturing demand?
  • Which factors will induce a change in biologics contract manufacturing demand during the assessment period?
  • How will changing trends impact biologics contract manufacturing demand?
  • How can market players capture the low-hanging opportunities related to biologics contract manufacturing demand in developed regions?
  • Which companies are leading in biologics contract manufacturing demand?
  • What are the winning strategies of stakeholders involved in biologics contract manufacturing demand services to upscale their position in this landscape?

Biologics Contract Manufacturing Demand: Research Methodology

In PMR’s study, a unique research methodology is utilized to conduct extensive research on the growth of biologics contract manufacturing demand, and reach conclusions on the future growth parameters of the market. This research methodology is a combination of primary and secondary research, which helps analysts ensure the accuracy and reliability of the conclusions.

Secondary resources referred to by analysts during the production of the biologics contract manufacturing demand market study include statistics from government organizations, trade journals, white papers, and internal and external proprietary databases. Analysts have interviewed senior managers, product portfolio managers, CEOs, VPs, marketing/product managers, and market intelligence managers, who contributed to the development of this report as a primary resource.

Comprehensive information acquired from primary and secondary resources acts as a validation from companies dealing in biologics contract manufacturing demand, and makes PMR’s projections on the growth prospects of the market space more accurate and reliable.

Have query on this report?

Make an Enquiry

Table of Content

1. Executive Summary
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Competitive Snapshot, Capacity (kL)
1.5. Analysis and Recommendations

2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations

3. Key Market Trends
3.1. Key Trends Impacting The Market
3.2. Product Development Trends 

4. Market Background
4.1. Macro-Economic Factors
4.1.1. Global GDP Growth Outlook
4.1.2. Global Healthcare Expenditure Outlook
4.1.3. Growth of Healthcare Sector in Emerging Nations
4.2. Forecast Factors - Relevance & Impact
4.2.1. Global Increase in Healthcare Expenditure
4.2.2. Strong biologics pipeline fuel demand for the CMOs
4.2.3. Corporate Venture Capital Investments are Helping Advance Biotechnology R&D
4.2.4. Changing regulatory dynamics are hampering the growth of Biopharmaceutical contract manufacturing market
4.2.5. CMO Cost Impact
4.2.6. Regulatory Scenario
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunity Analysis

Table 01: Global Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Product
Table 02: Global Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Product
Table 03: Global Biologics Contract Manufacturing Demand Value (US$ Mn) Analysis and Opportunity Assessment 2015–2030, By Product
Table 04: Global Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Platform
Table 05: Global Biologics Contract Manufacturing Demand Value (US$ Mn) Analysis and Opportunity Assessment 2015–2030, By Platform
Table 06: Global Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Therapeutic Area
Table 07: Global Biologics Contract Manufacturing Demand Value (US$ Mn) Analysis and Opportunity Assessment 2015–2030, By Therapeutic Area
Table 08: Global Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Application
Table 09: Global Biologics Contract Manufacturing Demand Value (US$ Mn) Analysis and Opportunity Assessment 2015–2030, By Application
Table 10: Global Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Region
Table 11: Global Biologics Contract Manufacturing Demand Value (US$ Mn) Analysis and Opportunity Assessment 2015–2030, By Region
Table 12: North America Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Country
Table 13: North America Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Product
Table 14: North America Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Platform
Table 15: North America Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Therapeutic Area
Table 16: North America Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Application
Table 17: Latin America Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Product
Table 18: Latin America Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Platform
Table 19: Latin America Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Therapeutic Area
Table 20: Latin America Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Application
Table 21: Europe Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Country
Table 22: Europe Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Product
Table 23: Europe Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Platform
Table 24: Europe Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Therapeutic Area
Table 25: Europe Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Application
Table 26: South Asia Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Country
Table 27: South Asia Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Product
Table 28: South Asia Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Platform
Table 29: South Asia Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Therapeutic Area
Table 30: South Asia Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Application
Table 31: East Asia Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Country
Table 32: East Asia Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Product
Table 33: East Asia Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Platform
Table 34: East Asia Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Therapeutic Area
Table 35: East Asia Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Application
Table 36: Oceania Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Country
Table 37: Oceania Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Product
Table 38: Oceania Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Platform
Table 39: Oceania Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Therapeutic Area
Table 40: Oceania Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Application
Table 41: Middle East & Africa (MEA) Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Country
Table 42: Middle East & Africa (MEA) Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Product
Table 43: Middle East & Africa (MEA) Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Platform
Table 44: Middle East & Africa (MEA) Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Therapeutic Area
Table 45: Middle East & Africa (MEA) Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Application
Table 46: U. S. Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Product
Table 47: U. S. Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Platform
Table 48: U. S. Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Therapeutic Area
Table 49: U. S. Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Application
Table 50: Canada Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Product
Table 51: Canada Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Platform
Table 52: Canada Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Therapeutic Area
Table 53: Canada Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Application
Table 54: U. K. Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Product
Table 55: U. K. Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Platform
Table 56: U. K. Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Therapeutic Area
Table 57: U. K. Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Application
Table 58: Germany Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Product
Table 59: Germany Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Platform
Table 60: Germany Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Therapeutic Area
Table 61: Germany Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Application
Table 62: France Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Product
Table 63: France Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Platform
Table 64: France Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Therapeutic Area
Table 65: France Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Application
Table 66: Spain Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Product
Table 67: Spain Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Platform
Table 68: Spain Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Therapeutic Area
Table 69: Spain Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Application
Table 70: Italy Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Product
Table 71: Italy Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Platform
Table 72: Italy Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Therapeutic Area
Table 73: Italy Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015–2030, By Application

 

Success Stories

Our Clients

Tell Us What You Need and We’ll Get Back with the Best Solutions Available.

*
*
*

get in touch

Location :

State Tower, 90 State Street, Suite 700, Albany NY - 12207, United States

Call Us :

US/Canada toll free : 866-997-4948

Tel : +1-518-621-2074